ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 3, 2017
SEC Approves Financial Weapon of Mass Destruction and More Earnings Reports
Let’s talk about quadruple-leveraged ETFs, Apple’s and Altria’s earnings reports, Coach’s fundamental improvement, Gilead’s fall from grace, IBM’s ongoing deterioration and more.
May 1, 2017
Seeking Balance: What’s Happening in the Crude Oil and Iron Ore Markets
Image Source: Sollven Melindo. Commodity prices are notoriously volatile as the global markets often struggle to maintain a sustainable balance of supply-demand. Let’s take a look at some recent developments and coming events that are impacting the prices of crude oil and iron ore.
Apr 25, 2017
Healthcare Earnings Update Featuring Johnson and Johnson, Cardinal Health and Abbott Labs
Image Source: Johnson & Johnson. The upcoming deluge of earnings over the next couple of weeks offers a glimpse into the ongoing business prospects for the various companies in our coverage universe. Let’s discuss the recent news release of a few prominent names in the healthcare industry.
Apr 18, 2017
United’s Passenger Debacle An Immaterial Investment Consideration
Image Source: Tomás Del Coro. The major airlines in the US have done a fantastic job capitalizing on the ongoing upswing in air travel demand, but their economically-sensitive business models remain the most operationally-leveraged out of any industry group in our coverage. This should be investors' biggest concern: A downturn in the global economy and competitive pricing pressures are far greater worries for investors than United’s recent passenger debacle. However, as with many news-oriented items (as opposed to materially-relevant, investment-related items), United's misstep is making headlines in a big way. Though the footage in this article is appalling, investors in airline stocks have much more important things to worry about, in our view.
Mar 30, 2017
Analyzing Amgen's Sudden Fall
Amgen’s share price has run up in anticipation of positive results from its key pipeline product Repatha. Now that the results are out, doubt has crept in concerning the overall viability of the product. Let’s examine.
Mar 27, 2017
Mednax: A Consolidator in the Healthcare Field
Image Source: Mednax. Neonatology and anesthesiology remain key revenue contributors for Mednax, but its teleradiology opportunity may propel its future growth prospects.
Mar 16, 2017
The “Year of Evangeline Adams” Continues
"...the S&P 500 has advanced more than 250% since the March 2009 panic bottom when it closed at 676.53 on the 9th of the month. Today, March 15, 2017, it closed at 2,385.26. The performance represents “a triple and then some” in the 8 years of this aging bull market. This is not performance on speculative small caps or risky biotechs, but on the largest companies in America. Please exercise prudence and care in all that you do." -- Brian Nelson, CFA
Mar 10, 2017
Priceline Delivers on Bookings Strength, Free Cash Flow Growth
Best Ideas Newsletter portfolio holding Priceline finished 2016 on a high note. Let’s take a quick look at its fourth-quarter report.
Mar 2, 2017
Dow 21,000+; Forward P/E on S&P 500 ~18!!!
To say that the broader equity market is “extended” is an understatement.
Feb 24, 2017
Average Check Increases Driving Results for Cracker Barrel
Image Source: Mike Mozart. Dividend Growth Newsletter portfolio holding Cracker Barrel drove average check increases to combat weak traffic that continues to plague the restaurant space.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.